The bacteria that refuses to go away
Helicobacter pylori (H. pylori) is a spiral-shaped bacteria that burrows into the stomach lining. It infects roughly half of the world's population and causes most stomach ulcers. Left untreated, it significantly raises the risk of stomach cancer.
In Asia, where rates of H. pylori infection and stomach cancer are among the highest in the world, treating this infection effectively is a major public health priority. But standard treatments — combinations of acid-blocking drugs and two antibiotics — are failing more often. Antibiotic resistance is rising, and cure rates in some regions have dropped below 80%.
Why standard therapy is losing ground
For decades, doctors relied on proton pump inhibitors (PPIs) — medications like omeprazole that reduce stomach acid — combined with antibiotics. The idea was simple: reduce the acid so the antibiotics can work better.
But here's the twist: PPIs are sensitive to the patient's genetics. Some people metabolize them quickly, which means the drug wears off faster and the stomach becomes acidic again — killing the effectiveness of the antibiotics working alongside it. In populations with a high proportion of fast metabolizers, PPI-based therapy underperforms.
How vonoprazan works differently
Think of stomach acid like a pump. PPIs block it by plugging the pump temporarily, but the plug can loosen depending on your genetics. Vonoprazan (VPZ) works differently — it sits inside the pump and blocks it from a different angle, more stably and for longer.
This means the stomach stays less acidic for more hours of the day. And when the environment is less acidic, amoxicillin — a single antibiotic — works harder and longer. The combination essentially keeps conditions favorable for the antibiotic around the clock, not just part of the day.
What the research covered
Researchers reviewed 22 clinical studies involving 7,498 participants across Asia, comparing vonoprazan-amoxicillin combinations against PPI-based regimens. The analysis was published in April 2026 in the Journal of Gastrointestinal and Liver Diseases.
They looked at dual therapy (VPZ + amoxicillin alone), triple therapy (VPZ + amoxicillin + a third antibiotic), and quadruple therapy (VPZ + amoxicillin + two more drugs).
The results were consistent and strong across all three regimens. Dual therapy achieved a 92% eradication rate. Triple therapy hit 93%. Quadruple therapy reached 96%. Combined, the overall eradication rate was 94%.
Compared directly to PPI-based regimens, vonoprazan combinations had a 6% higher eradication rate overall. In clinical terms, that difference could mean thousands fewer treatment failures each year across Asia.
A 94% eradication rate represents a meaningful step forward at a time when antibiotic resistance is making standard treatments less reliable.
Who benefits most — and an unexpected finding
The meta-regression (a statistical method that looks for patterns within the data) found that age influenced how well the treatment worked. Older patients showed slightly lower eradication rates. This isn't entirely surprising — aging affects how the stomach and immune system function — but it signals that some patients may still need more tailored approaches.
Body weight (BMI) did not affect the outcome, which simplifies dosing decisions.
If you live in Asia and have been diagnosed with H. pylori — or if a previous treatment failed — vonoprazan-based therapy is an option worth discussing with your doctor. In Japan and some other Asian countries, vonoprazan is already approved and in clinical use. In other countries, availability may vary.
If you're in a region where this drug isn't yet available, ask your doctor about resistance testing (called susceptibility testing) before starting treatment — it can improve the odds that your chosen regimen will work.
Limitations to keep in mind
Almost all of the included studies were from Asian countries — primarily Japan, China, and Korea. Genetic differences, dietary factors, and local antibiotic resistance patterns all vary significantly between Asia and other regions. The results may not fully apply to patients in North America, Europe, or Africa. Larger trials in diverse populations are needed.
Vonoprazan is already approved in Japan and gaining ground in other countries. Regulatory reviews are ongoing in several Western nations, where interest has increased as traditional H. pylori therapy has become less reliable. As resistance patterns evolve globally, the simpler vonoprazan-amoxicillin dual regimen — just two drugs instead of three or four — may become an attractive option well beyond Asia. More head-to-head trials in non-Asian populations will be critical to making that case.
